G
Glenn M. Chertow
Researcher at Stanford University
Publications - 830
Citations - 94517
Glenn M. Chertow is an academic researcher from Stanford University. The author has contributed to research in topics: Kidney disease & Dialysis. The author has an hindex of 128, co-authored 764 publications receiving 82401 citations. Previous affiliations of Glenn M. Chertow include University of Groningen & Fresenius Medical Care.
Papers
More filters
Journal ArticleDOI
SNF472: mechanism of action and results from clinical trials.
TL;DR: In this paper, a review outlines the pathophysiological mechanisms contributing to vascular calcification in end-stage kidney disease and describes recent studies evaluating the effects of the first-in-class inhibitor of VC, SNF472.
Journal ArticleDOI
A transcriptional blueprint for human and murine diabetic kidney disease.
TL;DR: An increase in the prevalence of type 2 diabetes and the high cardiovascular risk associated with CKD and end-stage renal disease suggest that diabetic kidney disease will absorb a disproportionate fraction of scarce health care resources in the coming decades.
Journal ArticleDOI
Use of novel oral anticoagulants in patients with end-stage renal disease.
Wolfgang C. Winkelmayer,Wolfgang C. Winkelmayer,Charles A. Herzog,Maria E. Montez-Rath,Tara I. Chang,Glenn M. Chertow +5 more
TL;DR: This study is the result of work supported by grant T32DK007467 from the National Institute of Diabetes and Digestive and Kidney Diseases, the Kidney Research Institute, and an unrestricted grant from the Northwest Kidney Centers Foundation.
Journal ArticleDOI
How to Use Quality Improvement Tools in Clinical Practice: A Primer for Nephrologists
TL;DR: The effect of performance measurement and data reporting in medicine and clinical nephrology has increased.
Journal ArticleDOI
Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO Trial.
Paolo Raggi,Antonio Bellasi,Smeeta Sinha,Jordi Bover,Mariano Rodriguez,Markus Ketteler,David A. Bushinsky,Rekha Garg,Joan Perelló,Alex Gold,Glenn M. Chertow +10 more
TL;DR: SNF472 treatment for 52 weeks reduced CACvs progression compared with placebo in a broad range of patients receiving maintenance hemodialysis, and future studies will determine the impact of SNF472 on cardiovascular events in this population.